Posted by Michael Wonder on 11 Sep 2020
Improved agreement means NICE now recommends lung cancer treatment
11 September 2020 - Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published today by NICE.
New draft guidance recommends osimertinib (Tagrisso, AstraZeneca) at two different places in the treatment pathway for locally advanced or metastatic epidermal growth factor receptor (EGFR) positive NSCLC.
Around 1,800 people in England have advanced EGFR positive NSCLC, and the majority are set to benefit from the new recommendations.
